A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.
Verstovsek S, Talpaz M, Wadleigh M, Isidori A, Te Boekhorst P, Savona MR, Bose P, Pozdnyakova O, Mesa R, El-Galaly TC, O'Sullivan J, Gamel K, Higgins B, Katakam S, Todorov B, Trunzer K, Harrison CN.
Verstovsek S, et al. Among authors: higgins b.
Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.284410. Online ahead of print.
Haematologica. 2024.
PMID: 38268448
Free article.